California Public Employees Retirement System Has $907.82 Million Stock Holdings in AbbVie Inc. $ABBV

California Public Employees Retirement System lowered its stake in AbbVie Inc. (NYSE:ABBV) by 13.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 4,890,752 shares of the company’s stock after selling 778,732 shares during the period. AbbVie makes up 0.6% of California Public Employees Retirement System’s portfolio, making the stock its 24th largest holding. California Public Employees Retirement System’s holdings in AbbVie were worth $907,821,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Marshall & Sullivan Inc. WA bought a new position in shares of AbbVie during the second quarter worth approximately $25,000. TD Capital Management LLC boosted its stake in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares during the period. Spurstone Advisory Services LLC acquired a new position in AbbVie in the 2nd quarter valued at $28,000. Financial Gravity Companies Inc. acquired a new position in AbbVie in the 2nd quarter valued at $36,000. Finally, Bear Mountain Capital Inc. increased its position in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

NYSE ABBV opened at $226.24 on Friday. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $399.85 billion, a price-to-earnings ratio of 171.39, a P/E/G ratio of 1.22 and a beta of 0.36. The firm’s 50 day simple moving average is $228.30 and its 200 day simple moving average is $208.35. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 496.97%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ABBV. Evercore ISI lifted their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research note on Monday, November 3rd. Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a research report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. boosted their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.